In a previous blog, I showed the reporting segment names used by 38 global chemical companies. (Click here to see that blog.) Three of the 38 companies have health care and three have life science in one of their reporting segments names (health care: Asahi Kasei; Mitsubishi; and Mitsui Chemical - life science: Nitto Denko; Sekisui; and Toray).
The following tables show the names of the chemical companies
with health care and those with life science reporting segment names:
company |
health care businesses |
||||
asahi kasei |
heath care is a
reporting segment name |
includes
pharmaceutical products |
and medical devices |
and filters |
|
mitsubishi |
heath care is a
reporting segment name |
includes prescription
pharmaceuticals |
and regenerative
medicines |
and health care
management |
segment includes two
divisions: pharmaceutical and life science |
mitsui |
heath care is a
reporting segment name |
includes ophthalmic
lens products |
and non-woven fabrics
for hygiene products |
and dental materials |
and personal care
products |
company |
life science businesses |
||
nitto denko |
life science is a
reporting segment name |
includes adhesion
technologies |
and drug delivery
technologies |
sekisui |
life science is a
reporting segment name |
includes diagnostic
reagents and devices |
and contract
manufacturing of active pharmaceutical ingredients |
toray |
life science is a
reporting segment name |
include
pharmaceuticals |
and medical devices |
I examined the most recent annual reports of the 38 global chemical companies referred to in the first paragraph above. What I found was that none of the European or American companies indicate in their annual reports significant health care of life science business pursuits. They likely sell products used in health care and the life sciences but in their annual reports such businesses are not described as significant or meaningful endeavors for the company.
The six companies that I did find describing in their annual reports health care or life science businesses as significant are Japanese companies. Each Japanese company, in fact, emphasizes a heath care or life science business by elevating that business to a reporting segment business. These Japanese chemical companies’ health care and life science businesses manufacture and sale pharmaceuticals and medical devices, as indicated in the tables above.
The above suggests to me a major difference in perspectives between Japanese and European/American chemical company mangers on chemical company enterprises.
Although three of the Japanese companies use the term “health
care” and the other three use “life science” as reporting segments, the terminology
differences do not represent substantive differences based on the businesses
described in the tables above.